Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608924 | 0.98 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL1608515 | 0.98 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL16153093 | 0.98 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL4835421 | 0.97 | MAPT (0.70) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL11643791 | 0.94 | MAPT (0.78) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL1141920 | 0.91 | MAPT (0.70) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL10870559 | 0.89 | MAPT (0.71) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL9277559 | 0.88 | MAPT (0.61) | MAPTSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL10176162 | 0.87 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL5624130 | 0.85 | MAPT (0.67) | MAPTSMN1; SMN2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | MAPT 3657/4885SMN1; SMN2 4601/4885KDM4E 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.